Breaking News

Researchers develop RNA-based antiviral technique

In a study published in Angewandte Chemie, researchers have reportedly shown how this approach could be effective ...

Hubrecht Institute licenses reagent antibodies for cancer research

The Clevers group dedicates its activity to the study of the molecular mechanisms of tissue development and cancer of ...

Swedish researchers develop antibacterial wound dressing

The World Health Organization describes antibiotic-resistant bacteria as one of the greatest threats to global health

Humans, hybrid models and the power of collaboration: part I

Dr Kevin Robinson recently spoke to Diane Diehl, Senior Director of Scientific Operations at Waters Corp., to discover ...

Long-acting injectable medicine as potential route to COVID-19 therapy

CELT was established as part of a £30.5 million ($40m) international research consortium, primarily funded by Unitaid

Linkam FDCS196 stage used in risperidone research

The researchers aimed to develop a novel transdermal delivery system for the anti-psychotic drug

From dark art to an age of enlightenment

Much is happening in the realms of Almac’s GMP peptides business in terms of growth, development and strategic ...

Alternating vaccines trial expands to include two additional vaccines

Volunteers, who will have received either the Oxford-AstraZeneca, or Pfizer vaccine, will be randomly allocated to ...

Long-term toxicology studies confirm MP1032 safety profile

MetrioPharm's lead compound has been evaluated in dogs and rats, confirming its "very good tolerability"

Bispecific antibodies: an exciting new class of emerging therapeutics

Since 2015, when the first bispecific received US FDA approval, these game-changing antibodies have rocketed in ...

The application of picodroplet technology for biopharmaceutical discovery and scientific research

Picodroplet technologies continue to push the boundaries of biologic discovery by accelerating research, expanding the ...

Bispecific antibodies in review: from cell line development to manufacturing

With the advent of a technology that targets two different epitopes simultaneously, growth in the global bispecific ...

Merck and SignalChem to investigate combination tumour treatment

The companies will evaluate SignalChem’s SLC-391 in combination with Merck’s Keytruda (pembrolizumab) in the ...

IONTAS identifies SARS-CoV-2 variant neutralising antibodies

The company is now seeking development partners to progress the antibodies